stockrow
Friday 6 November 2026
Export ISPC’s income statement to Excel — free account
iSpecimen Inc.
ISPC Healthcare Diagnostics & Research
iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024.
- Revenue
- −78.7%
- EPS
- +94.2%
- Free cash flow
- −257.7%
Quarter to June 2026, against a year earlier
0.81
0.00
0.00%
Follow ISPC
Alert me
iSpecimen Inc. (ISPC) P/E ratio
iSpecimen Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 2.9× (March 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.9×
Ten-year median
0.0×
Current reading's percentile
86
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DMTKQ DermTech, Inc. compare | n/m |
| ISPC iSpecimen Inc. | n/m |
| XWEL XWELL, Inc. compare | n/m |
| NDRA ENDRA Life Sciences Inc. compare | n/m |
| BIAF bioAffinity Technologies, Inc. compare | n/m |
| TTOO T2 Biosystems, Inc. compare | n/m |
| PRPH ProPhase Labs, Inc. compare | n/m |
| AWHL Aspira Women's Health Inc. compare | n/m |
| ADVB Advanced Biomed Inc. compare | 0.3× |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)